Nov 13 |
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment
|
Nov 12 |
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
|
Nov 8 |
Longboard Pharmaceuticals GAAP EPS of -$0.63
|
Nov 7 |
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
|
Nov 6 |
Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal
|
Oct 20 |
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
|
Oct 15 |
Health Care Roundup: Market Talk
|
Oct 15 |
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
|
Oct 15 |
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
|
Oct 15 |
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn
|